Molecular imaging and therapy of solid tumours

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Use of antibodies for cancer therapy, where a protein is made in the laboratory to recognize and act on cancer cells that have a target antigen, has emerged as an important therapeutic area in oncology. The lewis-y (Ley) antigen is found on more than 70% of epithelial cancers and the A33 antigen is found on colon cancers. We have developed antibodies against Ley (hu3S193) and A33 (huA33) which can target cancer cells. We aim to develop optimal cancer cell killing by our antibodies.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $807,029.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody cancer therapy | antibody engineering | immune regulation | positron emission tomography (PET) | solid tumours